Solving tricuspid regurgitation with enabling simplicity.

Discover Tripair™, designed to be a simple, safe and effective tricuspid valve repair solution that breaks barriers to adoption and will provide access to patients beyond the reach of existing therapies.

Coramaze develops Tripair™, a pioneering tricuspid valve repair system designed to overcome the limitations of existing therapies—to make treatment safer, more accessible, and available to a broader patient population.

About us
Our mission

We aim to improve health equity with a solution that is simple, safe and effective. By overcoming the key challenges of procedural complexity and limited adoption, we are on a mission to make TR treatment as simple as a right heart catheterization — so it can be performed by any interventionalist, anywhere.

Technology

designed to be simple. safe. effective.  

designed to be simple. safe. effective.  

Tripair is designed to be a simple, safe and effective tricuspid valve repair solution that breaks barriers to adoption and that will provide access to patients beyond the reach of existing therapies

Our technology

Tricuspid Regurgitation (TR) is a dreadful heart valve condition, affecting millions of people. If left untreated, it drastically impacts life expectancy and quality-of-life. Treatment options are limited, and despite its poor prognosis over 90% of patients remain untreated.

The problem
Breaking barriers
4.6M
Patients affected today
Patients with severe or worse TR in Europe and the US
318k
New patients annually
Each year, c. 318k severe or worse TR patients are newly diagnosed in Europe and the US
4.3x
Higher risk for women
Women are disproportionally affected and suffer 4.3x more often from TR compared to men
50%
Survive less than 2 years
TR is associated with an all-cause mortality rates at two years after diagnosis of 50%

Tripair™ intends to create a world with a simple, safe & effective solution to tricuspid regurgitation.

Physician statement
Physician statement
Paul Sorajja
Physician statement
“TR is life-threatening. Surgical interventions carry high risk for most patients, while current transcatheter solutions remain limited to a select group of patients. As a result, the majority of patients with severe TR are left untreated, highlighting the need for more accessible solutions.”